Scientists discover gene linked to breast and ovarian cancer

December 17, 2012

(Medical Xpress)—A team of researchers led by the Institute of Cancer Research, London, have found that rare mutations in a gene called PPM1D are linked to an increased risk of breast and ovarian cancer. The mutations are not inherited, and the discovery potentially reveals a new mechanism of cancer development.

The study suggests that around one in five women with PPM1D mutations will develop breast or ovarian cancer in the course of their lifetime, almost double the and more than ten times the ovarian cancer risk of women in the general population. The discovery could have implications for and targeted prevention, in particular for ovarian cancer, which is often diagnosed at an advanced stage.

The team analysed 507 genes involved in in 1150 women with breast or ovarian cancer, identifying PPM1D gene mutations in five women. They then sequenced the PPM1D gene in 7781 women with breast or ovarian cancer and 5861 people from the general population.

There were 25 faults in the PPM1D gene in women with cancer and only one in the general population, a highly statistically significant difference.

The study found that the mutated genes were not passed down from parent to child and were not present in every cell. Even more surprisingly, there were no PPM1D mutations in the or in the normal breast or ovarian cells; they were found only in . The findings suggest that PPM1D works in a completely different way to other genes known to increase the risk of breast and ovarian cancer, such as and BRCA2, potentially highlighting a new cancer-causing mechanism.

The team found that the mutations made the molecule that is produced from the PPM1D gene shorter than usual. Such truncating mutations are usually thought to cause a loss of function; however, the team were surprised to find that in this case the PPM1D mutations seem to make it more active.

Study leader Professor Nazneen Rahman, head of genetics at the Institute of Cancer Research (ICR) and head of the cancer genetics clinical unit at the Royal Marsden NHS Foundation Trust, said: "This is one of our most interesting and exciting discoveries.

"At every stage the results were different from the accepted theories. We don't yet know exactly how PPM1D mutations are linked to breast and ovarian cancer, but this finding is stimulating radical new thoughts about the way genes and cancer can be related."

"The results could also be useful in the clinic, particularly for ovarian cancer, which is often diagnosed at an advanced stage. If a woman knew she carried a PPM1D mutation and had a one in five chance of developing , she might consider keyhole surgery to remove her ovaries after completing her family."

Professor Alan Ashworth, chief executive of The Institute of Cancer Research and one of the study researchers, said: "This discovery really does turn conventional wisdom about the way genetic mutations can lead to cancer on its head. We are likely to gain many valuable insights into how cancers can occur as we continue to unravel this puzzle."

New genetic sequencing technologies that allow much deeper analysis of genes were crucial to enable the team to make the link between the PPM1D mutations and cancer. The discovery that the mutations were only present in some cells, a so-called mosaic pattern, would have been extremely difficult to detect with older sequencing methods.

It is possible that similar mosaic mutations in other genes, and in patients with other types of cancer, will emerge as more research groups are now using these deep sequencing techniques, the authors say.

Dr Michael Dunn, head of molecular and physiological sciences at the Wellcome Trust, said: "This study is an fantastic example of the power of next-generation sequencing to discover new cancer predisposing genes, offering opportunities for better diagnosis. The discovery also opens up a very exciting new avenue of research in the study of ."

The study was funded by the Institute of Cancer Research, the Wellcome Trust, UK and Breakthrough .

Explore further: Faulty gene connected to ovarian cancer risk

More information: Ruark E et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2012 (epub ahead of print).

Related Stories

Faulty gene connected to ovarian cancer risk

August 9, 2011
In a new study published in Nature Genetics researchers say that women who possess a fault in a gene named RAD51D have a greater risk of developing ovarian cancer than women who do not have this fault and tests are expected ...

Recommended for you

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.